Could a common gout pill protect hearts in HIV?

NCT ID NCT07704164

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests whether colchicine, an anti-inflammatory drug used for gout, can reduce inflammation in the coronary arteries of people with HIV who have high cardiovascular risk. Participants take either colchicine or a placebo daily for 96 weeks, and changes in artery inflammation are measured with a CT scan. The goal is to see if this approach could lower the risk of heart disease in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
colchicine 0.5 mg tablet taken once daily
What this could lead to
If it works, this could point toward a way to lower heart attack risk in people with HIV by reducing artery inflammation.
What could go wrong
This is a small, early-phase trial (90 people) testing a surrogate marker, not heart attacks directly. Colchicine can cause gastrointestinal side effects and may not reduce inflammation enough to matter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES (CVD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fundación Jiménez Díaz

    NOT_YET_RECRUITING

    Madrid, Spain

    Contact

  • Hospital La Paz

    RECRUITING

    Madrid, 28046, Spain

    Contact

  • Hospital Universitario Vall d' Hebron

    RECRUITING

    Barcelona, Spain

    Contact

  • Hospital Universitario de la Princesa

    NOT_YET_RECRUITING

    Madrid, Spain

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.